Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate for Treatment of Autoimmune Disorders
Burlington, Massachusetts--(Newsfile Corp. - November 9, 2026) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented Phase 1 clinical data for LFD-200, the Company's novel subcutaneously (SC) administered ADC delivering a potent glucocorticoid (GC) directly to immune cells, at the American College of Rheumatology (ACR) Convergence 2026 conference....